Athira Pharma (ATHA) Competitors $3.74 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.72 -0.03 (-0.67%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHA vs. NRXP, ANL, ALGS, GNTA, ACRV, IMMX, DRRX, ELYM, BRNS, and ICCCShould you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include NRx Pharmaceuticals (NRXP), Adlai Nortye (ANL), Aligos Therapeutics (ALGS), Genenta Science (GNTA), Acrivon Therapeutics (ACRV), Immix Biopharma (IMMX), DURECT (DRRX), Eliem Therapeutics (ELYM), Barinthus Biotherapeutics (BRNS), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry. Athira Pharma vs. Its Competitors NRx Pharmaceuticals Adlai Nortye Aligos Therapeutics Genenta Science Acrivon Therapeutics Immix Biopharma DURECT Eliem Therapeutics Barinthus Biotherapeutics ImmuCell Athira Pharma (NASDAQ:ATHA) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends. Which has preferable valuation and earnings, ATHA or NRXP? NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthira PharmaN/AN/A-$96.94M-$15.50-0.24NRx PharmaceuticalsN/AN/A-$25.13M-$2.24-1.36 Does the media refer more to ATHA or NRXP? In the previous week, NRx Pharmaceuticals had 4 more articles in the media than Athira Pharma. MarketBeat recorded 6 mentions for NRx Pharmaceuticals and 2 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.95 beat NRx Pharmaceuticals' score of 0.72 indicating that Athira Pharma is being referred to more favorably in the media. Company Overall Sentiment Athira Pharma Positive NRx Pharmaceuticals Positive Do insiders & institutionals have more ownership in ATHA or NRXP? 57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is ATHA or NRXP more profitable? NRx Pharmaceuticals' return on equity of 0.00% beat Athira Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Athira PharmaN/A -139.40% -106.84% NRx Pharmaceuticals N/A N/A -550.94% Do analysts rate ATHA or NRXP? Athira Pharma currently has a consensus target price of $4.00, indicating a potential upside of 6.95%. NRx Pharmaceuticals has a consensus target price of $34.50, indicating a potential upside of 1,031.15%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Athira Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has more volatility and risk, ATHA or NRXP? Athira Pharma has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. SummaryNRx Pharmaceuticals beats Athira Pharma on 8 of the 14 factors compared between the two stocks. Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHA vs. The Competition Export to ExcelMetricAthira PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.74M$3.37B$6.04B$10.45BDividend YieldN/A2.31%5.73%4.82%P/E Ratio-0.2422.0585.1427.26Price / SalesN/A472.43590.92134.18Price / CashN/A44.9825.7730.18Price / Book0.3210.4112.666.76Net Income-$96.94M-$52.58M$3.32B$276.50M7 Day Performance-3.11%0.92%0.44%0.88%1 Month Performance3.89%14.67%9.35%8.17%1 Year Performance-15.19%21.24%79.07%43.52% Athira Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHAAthira Pharma1.8451 of 5 stars$3.74flat$4.00+7.0%-10.1%$14.74MN/A-0.2440NRXPNRx Pharmaceuticals3.1287 of 5 stars$3.35+2.4%$34.50+929.9%+127.7%$64.78MN/A-1.502ANLAdlai Nortye1.8424 of 5 stars$1.76+1.7%$9.00+411.7%-11.6%$64.58MN/A0.00127News CoverageGap DownALGSAligos Therapeutics3.8867 of 5 stars$10.22+1.5%$50.00+389.2%+24.3%$61.94M$3.94M-0.5290News CoverageGap DownGNTAGenenta Science0.9121 of 5 stars$3.22-2.4%N/A-40.2%$60.36MN/A0.007ACRVAcrivon Therapeutics2.3075 of 5 stars$1.91flat$15.00+685.3%-75.7%$60.08MN/A-0.8558IMMXImmix Biopharma3.3595 of 5 stars$2.24+8.7%$8.00+257.1%+72.4%$59.40MN/A-2.919News CoverageGap DownHigh Trading VolumeDRRXDURECT1.1271 of 5 stars$1.91flatN/AN/A$59.31M$1.66M-19.1080News CoverageELYMEliem TherapeuticsN/A$1.98-2.9%N/A-66.8%$58.91MN/A-3.749Gap UpHigh Trading VolumeBRNSBarinthus Biotherapeutics2.459 of 5 stars$1.57+8.6%$3.00+91.1%+12.0%$58.85M$14.97M-0.91107Analyst ForecastGap UpICCCImmuCell1.1307 of 5 stars$6.35+0.6%N/A+82.3%$57.08M$26.49M33.4270Gap Up Related Companies and Tools Related Companies NRXP Competitors ANL Competitors ALGS Competitors GNTA Competitors ACRV Competitors IMMX Competitors DRRX Competitors ELYM Competitors BRNS Competitors ICCC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHA) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
